Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1550-1557

  Han, Y ^a   Kozel, T R ^a   Zhang, M X ^a   MacGill, R S ^a   Carroll, M C ^a   Cutler, J E ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; CANDIDA ALBICANS VACCINE; COBROTOXIN; COMPLEMENT COMPONENT C3; FUNGUS ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MANNAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B6.1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; CONTROLLED STUDY; FEMALE; FUNGICIDAL ACTIVITY; HUMAN; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0035424137     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1550     Document Type: Article

References (59)

1. Invasive Candida infections: Evolution of a fungal pathogen
2. Nosocomial candidemia: Risk factors and attributable mortality
3. Opportunistic candidiasis: An epidemic of the 1980s
4. International conference for the development of a consensus on the management and prevention of severe candidal infections
5. The emergence of fungi as major hospital pathogens
6. Nosocomial fungal infections. Old problems and new challenges
7. New insights into candidal infections
8. Candidemia in intensive care unit patients: Risk factors for mortality
9. Epidemiology and control of fungal infections
10. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations
11. Epidemiology of nosocomial fungal infections
12. Fungal infections in iatrogenically compromised hosts
13. Oropharyngeal candidiasis: A review of its clinical spectrum and current therapies
14. When and how to treat serious candidial infections: Concepts and controversies
15. Current strategies for treating invasive candidasis: Emphasis on infections in nonneutropenic patients
16. Hospital-acquired candidemia: The attributable mortality and excess length of stay
17. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates
18. Editorial response: Should all patients with candidemia be treated with antifungal agents?
19. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection
20. Antibody response that protects against disseminated candidiasis
21. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals
22. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis
23. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody
24. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals
25. Rats clearing a vaginal infection by Candida albicans acquire specific antibody-mediated resistance to vaginal reinfection
26. Cytoplasmic localization of the white phase-specific WH11 gene product of Candida albicans
27. Passive immunization of mice against Candida albicans
28. Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis
29. Protective role of anti-mannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats
30. Antibodies, killer toxins and antifungal immunoprotection: A lesson from nature?
31. Antibodies against Candida: Potential therapeutics?
32. Ultrastructural analysis of β-amyloid-induced programmed cell death in cultured hippocampal neurons
33. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies
34. Existence of branched side chains in the cell wall mannan of pathogenic yeast, Candida albicans: Structure-antigenicity relationship between the cell wall mannans of Candida albicans and Candida parapsilosis
35. Differential adherence between hydrophobic and hydrophilic yeast cells of Candida albicans
36. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity
37. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans
38. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast
39. The third, fourth, and fifth components of human complement: Isolation and biochemical properties
40. Outbreak of viral gastroenteritis due to drinking water contaminated by Norwalk-like viruses
41. Protein and cell membrane iodinations with a sparingly soluble chloramide. 1,3,4,6-tetrachloro-3α,6α-dephenylglycoluril
42. Distinct characteristics of initiation of the classical and alternative complement pathway by Candida albicans
43. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway
44. Isolation of the third component of mouse complement
45. A fluorometric assay for native C3: The hemolytically active form of the third component of human complement
46. Formation of the initial C3 convertase of the alternative complement pathway
47. In vitro studies of the interaction of murine phagocytic cells with Candida albicans
48. Activation and binding of C3 by Candida albicans
49. Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans
50. Role of complement in host defense against experimental disseminated candidiasis
51. Alternative pathway of complement activation by Candida albicans
52. Activation of the alternative (properdin) pathway of complement by Candida albicans and related species
53. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo
54. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis
55. A monoclonal antibody to C. albicans enhances mouse neutrophil candidacidal activity
56. Evidence for macrophage-mediated protection against lethal Candida albicans infection
57. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration
58. Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages